Shares of Tabula Rasa Healthcare Inc. (NASDAQ:TRHC) hit a new 52-week high on Tuesday . The company traded as high as $32.20 and last traded at $29.08, with a volume of 101700 shares traded. The stock had previously closed at $28.07.

A number of brokerages recently weighed in on TRHC. First Analysis began coverage on shares of Tabula Rasa Healthcare in a research note on Wednesday, November 1st. They set an “overweight” rating and a $41.00 price target for the company. Piper Jaffray Companies restated an “overweight” rating and issued a $35.00 target price on shares of Tabula Rasa Healthcare in a research note on Tuesday, November 7th. They noted that the move was a valuation call. Wells Fargo & Company cut shares of Tabula Rasa Healthcare from an “outperform” rating to a “market perform” rating and raised their target price for the stock from $17.00 to $21.00 in a research note on Thursday, September 7th. Zacks Investment Research upgraded shares of Tabula Rasa Healthcare from a “hold” rating to a “strong-buy” rating and set a $31.00 target price for the company in a research note on Wednesday, October 11th. Finally, Robert W. Baird restated an “outperform” rating and issued a $30.00 target price (up previously from $22.00) on shares of Tabula Rasa Healthcare in a research note on Tuesday, October 17th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Tabula Rasa Healthcare presently has a consensus rating of “Buy” and an average target price of $28.25.

The company has a current ratio of 0.73, a quick ratio of 0.66 and a debt-to-equity ratio of 0.47.

Tabula Rasa Healthcare (NASDAQ:TRHC) last released its earnings results on Monday, November 6th. The company reported $0.08 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.02. Tabula Rasa Healthcare had a negative net margin of 2.27% and a negative return on equity of 5.58%. The company had revenue of $33.27 million during the quarter, compared to analysts’ expectations of $31.76 million. During the same quarter last year, the business earned $0.06 EPS. The business’s revenue was up 37.6% on a year-over-year basis. equities research analysts expect that Tabula Rasa Healthcare Inc. will post 0.05 EPS for the current year.

In other news, CEO Calvin H. Knowlton sold 8,000 shares of the stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $17.21, for a total value of $137,680.00. Following the completion of the transaction, the chief executive officer now owns 918,362 shares in the company, valued at approximately $15,805,010.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 24,000 shares of company stock valued at $527,920 in the last quarter. Insiders own 45.80% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in TRHC. Pier Capital LLC purchased a new position in shares of Tabula Rasa Healthcare in the 3rd quarter valued at about $4,151,000. Wasatch Advisors Inc. purchased a new position in shares of Tabula Rasa Healthcare in the 3rd quarter valued at about $4,047,000. EAM Investors LLC purchased a new position in shares of Tabula Rasa Healthcare in the 3rd quarter valued at about $3,931,000. Allianz Asset Management GmbH purchased a new position in shares of Tabula Rasa Healthcare in the 3rd quarter valued at about $3,801,000. Finally, Paradigm Capital Management Inc. NY purchased a new position in shares of Tabula Rasa Healthcare in the 2nd quarter valued at about $1,165,000. Institutional investors and hedge funds own 25.80% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/11/14/tabula-rasa-healthcare-inc-trhc-reaches-new-52-week-high-at-32-20.html.

Tabula Rasa Healthcare Company Profile

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Receive News & Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.